Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV cancer study reveals who gets sick and why

NCT ID NCT05510908

Knowledge-focused Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affect daily life. The goal was to better understand cancer burden in this group and improve future trial participation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

460 people

The number who actually took part.

Started

Jul 2023

Finished

Jun 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with a dual diagnosis of both cancer (current or diagnosed within 5 years) and underlying HIV infection, who present for care at AMC domestic sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant can understand and is willing to sign a written informed consent document. * HIV positive. Documentation of HIV-1 infection by means of any one of the following: * Documentation of an HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) (i.e., at least two different medications that do not constitute a prescription for pre-exposure prophylaxis \[PrEP\]) by a licensed health care provider. Documentation may be a record of an ART prescription in the medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name; * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay. Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA). WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load. * Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories: * New, primary or recurrent diagnosis -Considering or currently receiving cancer treatment * Metastatic or locally advanced cancer - This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. * Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. * Age ≥ 18 years. * Participant presents to an AMC domestic clinical trial site for either clinical care or research. Exclusion Criteria: * Participants who do not fulfill the criteria as listed above are ineligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIDS related lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS AIDS-related Kaposi sarcoma anal carcinoma anus neoplasm cancer HIV infectious disease HIV-associated cancer human papillomavirus-related squamous cell carcinoma Kaposi's sarcoma lymphoma Lymphoma, AIDS-Related neoplasm primary effusion lymphoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIDS related lymphoma AIDS-related Kaposi sarcoma AIDS-related malignancy Anal cancer Cancer HIV infections HIV-associated malignant neoplasm HPV-related malignancy

Contacts and locations

Locations

  • Abramson Cancer Center at Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19106, United States

  • George Washington University Cancer Center

    Washington D.C., District of Columbia, 20037, United States

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah, 84112, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Moores UCSD Cancer Center

    La Jolla, California, 92903, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231, United States

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

  • University of Puerto Rico

    San Juan, 00921, Puerto Rico

  • Virginia Mason Medical Center

    Seattle, Washington, 98101, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Weill Cornell Medicine - Cornell Clinical Trials Unit

    New York, New York, 10010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.